Sun Pharmaceutical Industries Limited: Business Overview, Financials & Competitive Analysis
Sun Pharmaceutical Industries Limited scores 7/10 on the AskCyborg Cyborg Score (Solid). Balanced multinational pharma with India market leadership and emerging markets momentum, offset by US generic pressures and moderate earnings growth. FY26 showed strong consolidated revenue growth of 11.9% and EBITDA expansion of 16.1%, demonstrating operational momentum. India formulations grew 16.2% in Q3, accounting for 32% of sales with.
What is Sun Pharmaceutical Industries Limited's industry? Sun Pharmaceutical Industries Limited (sunpharma.com) operates in Generic Drugs. AskCyborg classifies Sun Pharmaceutical Industries Limited under Generic Drugs in its company registry.
Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company ...
Cyborg Score thesis
Balanced multinational pharma with India market leadership and emerging markets momentum, offset by US generic pressures and...
Read the full analyst-debate transcript →Get the Latest Sun Pharmaceutical Industries Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSun Pharmaceutical Industries Limited Overview
Pro stress-test →Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company reported consolidated revenues of ₹582 billion for FY26 (year ended March 31, 2026), growing 11.9% year-on-year.
Strategic Profile
Pro stress-test →Sun Pharma's diversified business mix—including India formulations (33% of revenue), emerging markets, US generics, and specialty medicines—enables balanced growth, with the company maintaining 8.4% market share as India's leading pharmaceutical player. The company is expanding its innovative product portfolio with US launches (Unloxcyt) and India introductions (Ilumya) to drive differentiated therapy offerings.
Competitive Landscape
Pro stress-test →Sun Pharma competes in global generic pharmaceuticals and specialty medicines against international majors and regional peers. In India, it holds the #1 market position with 8.4% share; in the US, it faces pricing pressure on generics from competitors; in emerging markets, it has outpaced regional peers with 21.6% growth in formulations (Q3 FY26).
Industry Context
Sun Pharmaceutical Industries Limited operates in Generic Drugs.
Key facts
Founded: 1993 · Headquarters: Mumbai, India · Employees: ~16,436 · Revenue: ₹582 billion (FY26) · Market cap: ₹4.57 trillion (approx.)